Survey on the worldwide Chronic Myeloid Leukemia Advocates Network regarding complementary and alternative medicine

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 6, 2013, Pages 1025-1031

  Elsner, Thomas ^b   Muecke, Ralph ^c   Micke, Oliver ^d   Prott, Franz J ^e   Muenstedt, Karsten ^f   Waldmann, Anita ^g   Geissler, Jan ^h   Huebner, Jutta ^a  

^a German Cancer Society   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c LIPPE HOSPITAL   (Germany)

^d FRANZISKUS HOSPITAL   (Germany)

^e RNS Gemeinschaftspraxis Wiesbaden   (Germany)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g Myeloma Euronet   (Germany)

^h CML Advocates   (Germany)

Author keywords

Chronic myeloid leukemia; Complementary and alternative medicine; Patient advocacy; Patient information; Risks and benefits

Indexed keywords

ALTERNATIVE MEDICINE; ARTICLE; ATTITUDE TO HEALTH; CHRONIC MYELOID LEUKEMIA; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HUMAN; INTEGRATED HEALTH CARE SYSTEM; INTERMETHOD COMPARISON; INTERNET; MEDICAL INFORMATION; PATIENT ADVOCACY; PATIENT SAFETY; PRIORITY JOURNAL; QUESTIONNAIRE; TRADITIONAL HEALER;

COMPLEMENTARY THERAPIES; HEALTH SURVEYS; HUMANS; INTERNET; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; QUESTIONNAIRES;

EID: 84878334051     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1414-4     Document Type: Article

References (29)

1. American Cancer Society (2013) http://www.cancer.org/treatment/ treatmentsandsideeffects/complementaryandalternativemedicine/ guidelines-for-using-complementary-and-alternative-methods; Assessed 26.02.2013
2. Broom A, Tovey P (2008) The role of the Internet in cancer patients' engagement with complementary and alternative treatments. Health (London) 12(2):139-155
3. Cassileth BR (2012) Alternative therapies: learning from patients who choose them. Oncologist 17(5):590-591
4. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA et al (2000) Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 22(23):4810-4815
5. Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2:212-216
6. Eschiti VS (2007) Lesson from comparison of CAM use by women with female-specific cancers to others: it's time to focus on interaction risks with CAM therapies. Integr Cancer Ther 6(4):313-344
7. Eysenbach G (2003) The impact of the Internet on cancer outcomes. CA Cancer J Clin 53(6):356-371
8. Hann D, Allen S, Ciambrone D, Shah A (2006) Use of complementary therapies during chemotherapy: influence of patients'satisfaction with treatment decision making and the treating oncologist. Integr Cancer Ther 5(3):224-231
9. Heaney ML (2008) Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68(19):8031-8038
10. Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life and preferences for decision making. J Clin Oncol 25:548-554
11. Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2011) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. PMID: 22019489
12. Kakai H, Maskarinec G, Shumay DM, Tatsumura Y, Tasaki K (2003) Ethnic differences in choices of health information by cancer patients using complementary and alternative medicine: an exploratory study with correspondence analysis.". Soc Sci Med 56(4):851-862
13. Maddock C, Lewis I, Ahmad K, Sullivan R (2011) Online information needs of cancer patients and their organizations. Ecancer 5:235. doi: 10.3332/ecancer.2011.235
14. Maskarinec G, Shumay DM, Kakai H, Gotay CC (2000) Ethnic differences in complementary and alternative medicine use among cancer patients. J Altern Complement Med 6(6):531-538
15. Matthews SC, Camacho A, Mills PJ, Dimsdale JE (2003) The internet for medical information about cancer: help or hindrance? Psychosomatics 44(2):100-103
16. Micke O, Bruns F, Glatzel M, Schönekaes K, Micke P, Mücke R et al (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 1:22-30
17. Micke O, Buntzel J, Kisters K, Schafer U, Micke P, Mucke R (2010) Complementary and alternative medicine in lung cancer patients: a neglected phenomenon? Front Radiat Ther Oncol 42:198-205
18. Miller PE, Vasey JJ, Short PF, Hartman TJ (2009) Dietary supplement use in adult cancer survivors. Oncol Nurs Forum 36:61-68
19. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V et al (2005a) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655-663
20. Molassiotis A, Margulies A, Fernandez-Ortega P, Pud D, Panteli V, Bruyns I (2005b) Complementary and alternative medicine use in patients with haematological malignancies in Europe. Complement Ther Clin Pract 11(2):105-110
21. Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X et al (2011) Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD anderson cancer center experience. Cancer 117(22):5142-5150
22. NCCAM (2013) http://nccam.nih.gov/about; Assessed 26.02.2013
23. Puissant A (2008) Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J 22(6):1894-1904
24. Rausch SM, Winegardner F, Kruk KM, Phatak V, Wahner-Roedler DL, Bauer B, Vincent A (2011) Complementary and alternative medicine: use and disclosure in radiation oncology community practice. Support Care Cancer 19(4):521-529
25. Robinson A, McGrail MR (2004) Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 12(2-3):90-98
26. Saxe GA, Madlensky L, Kealey S, Wu DP, Freeman KL, Pierce JP (2008) Disclosure to physicians of CAM use by breast cancer patients: findings from the women's healthy eating and living study. Integr Cancer Ther 7(3):122-127
27. Shatzer AN, Espey MG, Chavez M, Tu H, Levine M, Cohen JI (2012) Ascorbic acid kills epstein-barr virus positive burkitt lymphoma cells and epstein-barr virus transformed B-cells in vitro, but not in vivo. Leuk Lymphoma. (Epub ahead of print)
28. Verhoef MJ, Trojan L, Armitage GD, Carlson L, Hilsden RJ (2009) Complementary therapies for cancer patients: assessing information use and needs. Chronic Dis Can 29:80-88
29. Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E et al (2012) Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center 139:357-365. doi: 10.1007/s00432-012-1336-6